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Methylphenidate, Bupropion,
and SSRI Triple Therapy
William Bobo, M.D. I

Abstract

Methylph enidate and bupropion have been demonstrated as being iffective adjuncts to
serotonin reuptake inhibitors in the treatment qfdepression (1,2). The use ofthese medications in
the.form cftriple therapyfor cases cfsevere refractory illness has not been reported. We present the
case of a depressed patient whose condition was resistant to several .forms qf monotherapy ,
monotherapy with "standard" augmentation and ECT. Afler only a partial response toJl uoxetine
and methylphenidate, bupropion was added, resulting in full, sustained remission.
CASE REPORT

BL is a middle ag ed male with dysthymia and severe recurren t m ajor d epression, and a negative past medical history. Hi s illness had partially responded to
fluox etine, desipramine, ph en elzin e and paroxetine; how ever, his chro nic low-grade
depression and almost consta n t suicidal preoccupation never resolved . H e received
ECT, also with an initial good response, but lat er relap sed with a re turn of his
episod ic seve re depression. Subsequ ent trials of bupropi on wit h liothyro nin e au gmentation, venlafaxine, and a combina tion of se rt raline , nortriptylin e a nd lithium a ll
failed .
Sin ce th e initial fluox etine trial was on ly two weeks time in len gth , it was
restarted without significant improvement. M ethylphenidat e was thus added and
titrat ed to a dos e of 10 mg bid . On this regimen, BL expe rie nce d improve men t in
e ne rgy level and d emonstrated a bright er affect. Again, however, his low-grad e
depression and sui cidal preoccupation continue d. Bupropion, was th en start ed and
th en titrat ed to a maximum dos e of 100 mg bid . Th e tripl e th erap y was we lltol erat ed , and brought about significant clinical improvem ent. His e ne rgy level
improved further, and his dysphporia, sleep disturbance, anh edonia a nd suic ida l
ideation gradually resolved. At two-month follow-up, th es e improvem en ts were
sustained. Most importantly, his sui cidal ideation remained markedl y decr eased. H e
continues to do well on this triple regim en of bupropion 100 mg bid , fluoxet ine 20
mg, and m ethylphenidate 10 mg bid , without significa nt side-e ffec ts .
This pati ent's experie nce suggests that in case s of severe dep ression th a t fails or
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partially responds to monotherapy, a ug me n tatio n th erapy a nd even ECT, th e
tripl e-therapy d escribed may bring a bout clinical improvem ent. T his patient's sustain ed response is rath er e ncou rag ing, give n hi s lon g histo ry of severe a nd frequ ently
recurrent illn es s. It is postulated th at , via this regimen, level s of ce nt ral serotonin,
norepin ephrine a nd dopamine may be more effec t ively increased , t hereby exe r t ing
it s adde d th erapeutic benefit. It is also our opinion th at this form of t rip le th erapy
repres ents an addition al a ug me n ta t ion st ra tegy whi ch may be useful in cas es like
th e on e described , or wh en a co m bina t ion of SRI a nd eit he r me t hylphenidate or
bupropion fails to bring about a full clinical response. C lose r exam ination involving
larger numbers of su ch patients is st ill need ed in o rde r to subs ta ntiate th is posit ion.
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